MR Imaging on the Alberta linac-MR P3 system for Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
CancerMR scan with the Alberta linac-MR P3 system - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new machine that uses MRI scans to guide radiotherapy treatments can safely acquire high quality images.

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Through study completion, approximately 1 year

Week 5
Quantify the patient experience on the Linac-MR
Year 1
Number of high-quality MR image data sets acquired for each major tumour site (prostate, liver, lung, CNS, and breast)

Trial Safety

Trial Design

1 Treatment Group

MR Imaging on the Alberta linac-MR P3 system
1 of 1

Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: MR Imaging on the Alberta linac-MR P3 system · No Placebo Group · N/A

MR Imaging on the Alberta linac-MR P3 system
Device
Experimental Group · 1 Intervention: MR scan with the Alberta linac-MR P3 system · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, approximately 1 year

Who is running the clinical trial?

AHS Cancer Control AlbertaLead Sponsor
177 Previous Clinical Trials
35,664 Total Patients Enrolled
Nawaid Usmani, MDPrincipal InvestigatorCross Cancer Institute, Alberta Health Services
3 Previous Clinical Trials
516 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
People who are 18 years or older are considered adults.
will be randomized to receive proton therapy or photon therapy Patients who are fit to undergo high dose radiation therapy will be randomized to receive proton therapy or photon therapy.